Revolution Medicines Inc (NASDAQ: RVMD) is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company generates no product revenue as of the 10-K filed 2026-02-25, operating entirely on capital raises to fund research and development. Its pipeline is built around proprietary RAS(ON) Inhibitors, small molecules that bind directly to the active, GTP-bound form of RAS using a tri-complex technology platform. Lead candidates include daraxonrasib (pan-RAS(ON) inhibitor), zoldonrasib (KRAS G12D-selective, received FDA Breakthrough Therapy Designation in December 2025), and elironrasib (KRAS G12C-selective, received FDA Breakthrough Therapy Designation in July 2025). Primary target indications are pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Three Phase 3 registrational studies in PDAC (RASolute 302, 303, 304, 305) were active as of the filing date. The company is headquartered in the United States and lists on the Nasdaq Global Select Market.

Revenue model

No product revenue. Pre-commercial stage company funded through equity capital. No disclosed partnership or royalty revenue streams in the filing excerpts.

Products and services

Daraxonrasib: pan-RAS(ON) tri-complex inhibitor in Phase 3 trials for PDAC and Phase 1/combination studies for NSCLC. Zoldonrasib: oral KRAS G12D-selective RAS(ON) inhibitor, FDA Breakthrough Therapy Designation December 2025 for KRAS G12D-mutated locally advanced or metastatic NSCLC. Elironrasib: oral KRAS G12C-selective RAS(ON) inhibitor, FDA Breakthrough Therapy Designation July 2025 for KRAS G12C-mutated locally advanced or metastatic NSCLC.

Customers and end markets

No commercial customers as of filing date. Target patient populations are adults with RAS-mutated cancers, specifically KRAS G12D and KRAS G12C mutations, across PDAC and NSCLC indications.

Value-chain role

Drug discovery and clinical-stage development. Structure-based small molecule design using proprietary tri-complex technology. Pre-commercial; no manufacturing or distribution at commercial scale disclosed in filing excerpts.

Geographic exposure

United States headquarters. Global Phase 3 registrational studies referenced in filing excerpts. No specific geographic revenue breakdown applicable given pre-commercial status.

Source: SEC 10-K, filed 2026-02-25

Industry: Biological Products, (No Diagnostic Substances) Peers: Agios Pharmaceuticals Inc Allogene Therapeutics Inc Arcus Biosciences Inc Travere Therapeutics Inc Ironwood Pharmaceuticals Inc IVERIC bio, Inc. Krystal Biotech Inc Lyell Immunopharma Inc Recursion Pharmaceuticals Inc